601 related articles for article (PubMed ID: 28270498)
1. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
Jovanović B; Mayer IA; Mayer EL; Abramson VG; Bardia A; Sanders ME; Kuba MG; Estrada MV; Beeler JS; Shaver TM; Johnson KC; Sanchez V; Rosenbluth JM; Dillon PM; Forero-Torres A; Chang JC; Meszoely IM; Grau AM; Lehmann BD; Shyr Y; Sheng Q; Chen SC; Arteaga CL; Pietenpol JA
Clin Cancer Res; 2017 Aug; 23(15):4035-4045. PubMed ID: 28270498
[No Abstract] [Full Text] [Related]
2. SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
Llombart-Cussac A; Bermejo B; Villanueva C; Delaloge S; Morales S; Balmaña J; Amillano K; Bonnefoi H; Casas A; Manso L; Roché H; Gonzalez-Santiago S; Gavilá J; Sánchez-Rovira P; Di Cosimo S; Harbeck N; Charpentier E; Garcia-Ribas I; Radosevic-Robin N; Aura C; Baselga J
Breast Cancer Res Treat; 2015 Nov; 154(2):351-7. PubMed ID: 26536871
[TBL] [Abstract][Full Text] [Related]
3. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
[TBL] [Abstract][Full Text] [Related]
4. Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy.
Georgy JT; Singh A; John AO; Joel A; Andrews AG; Thumaty DB; Rebekah G; Sigamani E; Chandramohan J; Manipadam MT; Cherian AJ; Abraham DT; Paul MJ; Balakrishnan R; Backianathan S; Chacko RT
Klin Onkol; 2021; 34(1):49-55. PubMed ID: 33657819
[TBL] [Abstract][Full Text] [Related]
5. Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy.
Anand K; Patel T; Niravath P; Rodriguez A; Darcourt J; Belcheva A; Boone T; Ensor J; Chang J
Sci Rep; 2021 Jan; 11(1):82. PubMed ID: 33420229
[TBL] [Abstract][Full Text] [Related]
6. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.
Gonzalez-Angulo AM; Akcakanat A; Liu S; Green MC; Murray JL; Chen H; Palla SL; Koenig KB; Brewster AM; Valero V; Ibrahim NK; Moulder-Thompson S; Litton JK; Tarco E; Moore J; Flores P; Crawford D; Dryden MJ; Symmans WF; Sahin A; Giordano SH; Pusztai L; Do KA; Mills GB; Hortobagyi GN; Meric-Bernstam F
Ann Oncol; 2014 Jun; 25(6):1122-7. PubMed ID: 24669015
[TBL] [Abstract][Full Text] [Related]
7. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
Oliveira M; Saura C; Nuciforo P; Calvo I; Andersen J; Passos-Coelho JL; Gil Gil M; Bermejo B; Patt DA; Ciruelos E; de la Peña L; Xu N; Wongchenko M; Shi Z; Singel SM; Isakoff SJ
Ann Oncol; 2019 Aug; 30(8):1289-1297. PubMed ID: 31147675
[TBL] [Abstract][Full Text] [Related]
8. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
[TBL] [Abstract][Full Text] [Related]
9. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
[TBL] [Abstract][Full Text] [Related]
11. Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy.
Jongen L; Floris G; Wildiers H; Claessens F; Richard F; Laenen A; Desmedt C; Ardui J; Punie K; Smeets A; Berteloot P; Vergote I; Neven P
Breast Cancer Res Treat; 2019 Aug; 176(3):699-708. PubMed ID: 31106385
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer.
Yardley DA; Shipley DL; Peacock NW; Shastry M; Midha R; Priego VM; Hainsworth JD
Breast Cancer Res Treat; 2015 Aug; 152(3):557-67. PubMed ID: 26155975
[TBL] [Abstract][Full Text] [Related]
13. Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
Kaklamani VG; Jeruss JS; Hughes E; Siziopikou K; Timms KM; Gutin A; Abkevich V; Sangale Z; Solimeno C; Brown KL; Jones J; Hartman AR; Meservey C; Jovanovic B; Helenowski I; Khan SA; Bethke K; Hansen N; Uthe R; Giordano S; Rosen S; Hoskins K; Von Roenn J; Jain S; Parini V; Gradishar W
Breast Cancer Res Treat; 2015 Jun; 151(3):629-38. PubMed ID: 26006067
[TBL] [Abstract][Full Text] [Related]
14. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
Mayer EL; Abramson V; Jankowitz R; Falkson C; Marcom PK; Traina T; Carey L; Rimawi M; Specht J; Miller K; Stearns V; Tung N; Perou C; Richardson AL; Componeschi K; Trippa L; Tan-Wasielewski Z; Timms K; Krop I; Wolff AC; Winer EP
Ann Oncol; 2020 Nov; 31(11):1518-1525. PubMed ID: 32798689
[TBL] [Abstract][Full Text] [Related]
15. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Hatem R; El Botty R; Chateau-Joubert S; Servely JL; Labiod D; de Plater L; Assayag F; Coussy F; Callens C; Vacher S; Reyal F; Cosulich S; Diéras V; Bièche I; Marangoni E
Oncotarget; 2016 Jul; 7(30):48206-48219. PubMed ID: 27374081
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer.
Cancello G; Bagnardi V; Sangalli C; Montagna E; Dellapasqua S; Sporchia A; Iorfida M; Viale G; Barberis M; Veronesi P; Luini A; Intra M; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2015 Aug; 15(4):259-65. PubMed ID: 25933934
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
[TBL] [Abstract][Full Text] [Related]
18. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
Filho OM; Stover DG; Asad S; Ansell PJ; Watson M; Loibl S; Geyer CE; Bae J; Collier K; Cherian M; O'Shaughnessy J; Untch M; Rugo HS; Huober JB; Golshan M; Sikov WM; von Minckwitz G; Rastogi P; Maag D; Wolmark N; Denkert C; Symmans WF
JAMA Oncol; 2021 Apr; 7(4):603-608. PubMed ID: 33599688
[TBL] [Abstract][Full Text] [Related]
19. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Kümmel S; Paepke S; Huober J; Schem C; Untch M; Blohmer JU; Eiermann W; Gerber B; Hanusch C; Hilfrich J; Jackisch C; Schneeweiss A; Denkert C; Engels K; Klare P; Fasching PA; von Minckwitz G; Burchardi N; Loibl S
Eur J Cancer; 2017 Oct; 84():1-8. PubMed ID: 28768217
[TBL] [Abstract][Full Text] [Related]
20. Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study.
Guarneri V; Dieci MV; Bisagni G; Boni C; Cagossi K; Puglisi F; Pecchi A; Piacentini F; Conte P
Ann Surg Oncol; 2015 Sep; 22(9):2881-7. PubMed ID: 25572687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]